paragon -心力衰竭试验——对伴有高血压和保留射血分数的心力衰竭患者的又一次失望

IF 2.3 4区医学 Q2 PERIPHERAL VASCULAR DISEASE

Blood Pressure Pub Date : 2019-09-03 DOI:10.1080/08037051.2019.1664717

S. Kjeldsen, K. Narkiewicz, M. Burnier, S. Oparil

引用次数: 0

摘要

新型血管紧张素受体拮抗剂/neprilysin抑制剂(ARNIs)寻求利用肾素-血管紧张素-醛固酮系统(RAAS)拮抗剂和中性内肽联合治疗的临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction

Novel angiotensin receptor antagonist/neprilysin inhibitors (ARNIs) seek to exploit the clinical benefits of combining renin-angiotensin-aldosterone-system (RAAS) antagonism and neutral endopeptida...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Pressure 医学-外周血管病

CiteScore

3.00

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.